Alarcón G S, Bradley L A
Division of Clinical Immunology and Rheumatology and the Multipurpose Arthritis and Musculoskeletal Diseases Center, The University of Alabama at Birmingham, 35294, USA.
Am J Med Sci. 1998 Jun;315(6):397-404. doi: 10.1097/00000441-199806000-00008.
Despite significant efforts devoted to understanding the etiopathogenesis of fibromyalgia, its treatment still presents a challenge to practicing clinicians, who must recognize the disorder and quantify the different symptoms in order to treat it. This article discusses recent research to identify sensitive and reliable measures for determining response to treatment among patients with FM, and the elements of therapeutic programs (pharmacologic and nonpharmacologic) for patients with FM along with the empirical or theoretical basis for their use. Future directions, including the need for systematic, controlled outcome studies of therapies and evaluation of variables which may mediate the effects of treatment, as well as demonstration that the effects produced in outcome studies generalize to settings beyond those in which the studies are initially conducted, are also discussed.
尽管在理解纤维肌痛的病因发病机制方面投入了大量努力，但其治疗对临床医生来说仍是一项挑战，临床医生必须识别该疾病并对不同症状进行量化才能进行治疗。本文讨论了最近的研究，以确定用于判定纤维肌痛患者治疗反应的敏感且可靠的测量方法，以及纤维肌痛患者治疗方案（药物和非药物）的要素及其使用的经验或理论依据。还讨论了未来的方向，包括对治疗进行系统、对照的疗效研究以及对可能介导治疗效果的变量进行评估的必要性，以及证明疗效研究产生的效果能推广到研究最初开展环境之外的其他环境。
